SUPIMA
6.10.2020 15:02:14 CEST | Business Wire | Press release
Supima presents the 3rd annual Supima Design Lab in its very first all-digital format, which will take place on Thursday, October 8th and be streamed live on Supima’s Instagram along with Fashion Network. Once again Supima brings together a select group of up and coming and leading designers from around the world. This year’s Supima Design Lab will showcase exclusive collections designed using American-grown Supima cotton featuring designs by the winner and finalists of the 2020 Supima Design Competition, the selection of the 2020 Hyères Fashion & Photography Festival and by leading International designers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005256/en/
Created exclusively for the Supima Design Lab, each design showcases the endless possibilities of fabrics made with Supima cotton. Stemming from a commitment to design, sustainable innovation and superior quality, Supima is unwavering in its ongoing programs that create platforms for designers to express themselves despite the challenges of Covid-19.
This Year’s Digital Runway show will be presenting “Made with Supima” Exclusive Designs by;
The Winner and Finalists of the 13th Annual Supima Design Competition
Amanda Forastieri, Drexel University – This Year’s Winner
Sakura Mizutani , Fashion Institute of Design & Merchandising
Jenny Feng , Fashion Institute of Technology
Jennie Nguyen , Kent State University
Terrence Zhou , Parsons School of Design
Kyra Buenviaje , Rhode Island School of Design
Finalists of 35th International Festival of Fashion, Fashion Photography and Accessories of Hyères
Katarzyna Agnieszka (France) Andrea Grossi (Italy)
Aline Boubert (France) Marvin M’Toumo (France)
Xavier Brisoux (France) Maximilian Rittler (Belgium)
Emma Bruschi (France) Céline Shen (France)
Timour Desdemoustier (Belgium) Tom van der Borght (Belgium)
Selected Leading Designers
Thierry Colson
Lutz Huelle
Dice Kayek
Jean Paul Knott
On Aura Tout Vu
As a special addition to this year’s Supima Design Lab, there will be a round table orchestrated by Benjamin Simmenauer, Permanent Professor at Institut Français de la Mode, Fashion Expert & Brand Strategist. The round table includes a select panel of industry leaders for an in-depth discussion of the Supima Design Lab - From the Fields to the Runway. This year’s panelists include :
Jean-Pierre Blanc , Founder, International Festival of Fashion, Photography and Accessories of Hyères
Godfrey Deeny , International Editor-in-Chief, FashionNetwork
Marc Lewkowitz , President & CEO, Supima
Buxton Midyette , VP Marketing & Promotions, Supima
« We are truly honored to continue working with our SDC Partner School finalists, the selection from the Festival de Hyères and our Leading Designer group. During the pandemic, we knew it was more important than ever to stay nimble and shift the Supima Design Lab into a virtual format to support these emerging designers achieve success in the fashion industry »
Buxton Midyette, VP Marketing & Promotions, Supima
About Supima :
Supima is America’s premium cotton. Founded in 1954, the Supima brand, short for « Superior Pima », designates an elite variety of pima cotton sustainably grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color and indulgent softness.
Follow Us on Social:
Instagram: @Supima
Facebook: @Supima
Twitter: @Supima
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005256/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom